The short answer
SEER's overall five-year relative survival for malignant brain tumors is 32.9 percent, but that one number blends tumor types whose outlooks are nothing alike, because type and grade matter far more than stage. Even localized brain tumors have a five-year relative survival of only 35.3 percent, while different tumor types range from about 6 percent for glioblastoma, which is malignant, to about 88 percent for meningioma, which is usually not, in separate registry data that counts both.
A survival statistic describes a large group diagnosed years ago — not a prediction for any one person.
Standard localized/regional/distant staging is far less meaningful for brain tumors than for most other cancers.
Tumor type and grade (how abnormal the cells look, and how fast they tend to grow) matter more than stage for brain tumor outlook.
Molecular markers like IDH mutation status increasingly help predict outlook and guide treatment.
Choose how you want to understand this
The full explanation.
Before you look at the numbers
Three things are true about the numbers below. Please read all three before you look at a single brain tumor percentage.
First, a "5-year relative survival rate" for brain tumors describes a large group of people. Those people were diagnosed with malignant brain and other nervous system tumors years ago. It is not a prediction about you. Everyone's brain tumor, body, and treatment plan are different.
Second, this data lags behind today's care. These figures reflect people diagnosed between 2016 and 2022. Treatment guided by molecular markers has continued to develop since then. So brain tumor treatment today may already work better than these numbers suggest.
Third, an all-stages brain tumor number blends two very different groups. It mixes people whose tumor was found while it was still localized with people whose tumor had already spread. For most cancers the stage-specific rows are more informative than a blended average. Brain tumours are the exception: as the SEER table below shows, the localized, regional and distant figures sit close together, so neither the blended number nor the stage rows tell you much. Tumour type, WHO grade and molecular markers do the work here. And "5-year" is a measuring window researchers use for consistency, not a milestone for any brain tumor. It is not a life expectancy for anyone with a brain tumor, and it is not a deadline.
The SEER numbers for malignant brain and other nervous system tumors
SEER tracks malignant brain and other nervous system tumors as one broad group. That group includes many very different tumor types. SEER does publish a single all-stages figure — 32.9% five-year relative survival for people diagnosed 2016–2022 — but it blends tumor types whose outlooks are nothing alike, so it carries less meaning here than it does for most cancers.
For brain tumors, SEER's localized, regional and distant categories behave differently than they do for other cancers. About 77% of cases are classified as localized. Yet even localized brain tumors have a five-year relative survival of only 35.3%. That is a strong signal. Standard staging is not the most useful way to think about brain tumor outlook.
| Stage at diagnosis | 5-year relative survival |
|---|---|
| Localized (about 77% of cases) | 35.3% |
| Regional (about 14% of cases) | 20.1% |
| Distant (about 2% of cases) | 28.0% |
| Unknown/unstaged (about 7% of cases) | 32.2% |
What "relative survival" actually means
Relative survival compares two groups. One group has malignant brain and other nervous system tumors. The other group is the same age and sex, but has no brain tumor. Say the rate is 100%. That would mean the brain tumor group was as likely to reach 5 years as the other. It is not the share of people who are free of a brain tumor. It is not the share of people who die from the tumor itself.
Brain tumor outlook depends heavily on tumor type and grade. It depends much less on the location-based staging used for most cancers. Take separate data from the Central Brain Tumor Registry of the United States (CBTRUS), covering tumors diagnosed 2004–2020. There, five-year relative survival for people aged 40 and over ranges from about 6% for glioblastoma to about 88% for meningioma. Those two are not like for like. Glioblastoma is malignant and sits inside the SEER group above; the great majority of meningiomas are non-malignant and are not counted in SEER's malignant brain cancer statistics at all. CBTRUS counts both. Both can be called 'brain tumors,' and their outlooks are very different. Molecular markers also help more and more in predicting how a tumor will respond to treatment. IDH mutation status and MGMT methylation are two of them.
What actually changes your outlook
A statistic describes a group. Your outlook depends on things specific to you.
- Stage — how far the brain tumor has spread, as shown in the table above.
- Grade — how odd the brain tumor cells look, and how fast they tend to grow.
- Tumor type and WHO grade — the single biggest factor in brain tumor outlook. Glioblastoma, for example, behaves very differently from a low-grade glioma or a meningioma.
- IDH mutation status and MGMT methylation — molecular markers that help predict outlook and guide treatment for gliomas.
- How your brain tumor responds — early scans and labs often say more than the first numbers.
- Your overall health — other health problems, age, and fitness shape brain tumor treatment and recovery.
- Access to care — a quick brain tumor diagnosis, specialist care, and finishing treatment all matter.
Questions for your care team
- Which SEER stage describes my brain tumor, and what is its five-year number?
- Which biomarkers or molecular tests matter in brain tumors, and were they run on my sample?
- How do my age and overall health change these brain tumor statistics for me?
- Are there newer brain tumor treatments available now that this data doesn't reflect yet?
- Beyond the general brain tumor statistics, what does my team expect in my case?
- Where can I find support for how it feels to hear these brain tumor numbers?
- What specific tumor type and WHO grade do I have, and were IDH or MGMT testing done?
If these numbers are hard to sit with
Brain tumor numbers can leave you scared, numb, or overwhelmed. That is normal. It does not mean you are handling a brain tumor diagnosis the wrong way. Many people take these brain tumor numbers in slowly, or with someone in the room. Others skip the numbers until they feel ready. Cancer Anxiety and Uncertainty covers the fear these brain tumor numbers can stir up. It is also worth telling your brain tumor team how much detail you want, and when.
Sources
- National Cancer Institute SEER Cancer Stat Facts: Brain and Other Nervous System Cancer
- American Cancer Society, tumor-type survival data from the Central Brain Tumor Registry of the United States (CBTRUS)
- National Cancer Institute — Understanding Cancer Prognosis
- Understanding Cancer Survival Statistics (Cancer Explained)
Words to know
Tap any term to see what it means.
Common questions
What does the SEER 'stage' table mean for a brain tumor?
Less than it does for most other cancers. Brain tumors don't spread through the body the way many other cancers do, so the localized/regional/distant categories don't map neatly onto how doctors actually think about brain tumor outlook. Tumor type and grade are usually far more informative.
Why does 'localized' brain tumor survival look lower than 'localized' survival for other cancers?
Because for brain tumors, 'stage' mostly reflects location and biology rather than how far cancer has traveled. A tumor can be 'localized' to the brain and still be a fast-growing, hard-to-treat type, like glioblastoma. This is exactly why tumor type and grade matter more than stage here.
Does this number predict what will happen to me?
No. This is a statistic about a large, mixed group of tumor types, not a prediction about you. Your specific tumor type, its grade, molecular markers like IDH mutation status, your age, and how you respond to treatment all shape your individual outlook far more than a blended statistic can.
Is this the most current data available?
It is the most recent SEER data available, but it still reflects people diagnosed between 2016 and 2022. Treatment, including newer approaches guided by molecular testing, continues to change.
Questions to ask your doctor
Being prepared helps you get the most out of your appointments. Save or print these questions.
Tap a question to save it to your list (kept on this device).
Speak With Trained Specialists & Human Navigators
Cancer Explained provides educational guidance, but does not replace trained specialists, social workers, or your medical team.
Talk to a trained cancer information specialist
Free, confidential assistance from NCI Cancer Information Service via phone, chat, or email.
Contact your oncology team
Locate after-hours contact numbers, portal messages, or urgent triage phone lines.
Find a patient navigator
Get one-on-one help with appointments, logistics, translation, and care coordination.
Find a genetic counselor
Discuss inherited mutation risk, family history, and genetic testing options.
Find an oncology social worker
Access emotional counseling, family support groups, and mental health resources.
Find a financial navigator
Locate copay assistance foundations, grant programs, and lodging/travel support.
Find a clinical-trial specialist
Search matching studies and speak with NCI trial information specialists.
Get urgent help
Immediate emergency guidance for fever (>100.4°F during chemo), severe pain, or shortness of breath.
Help Us Improve This Guide
Did this explanation answer your question and help you determine your next step?
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Plain-language explanation of the published sources cited on this page. AI-assisted, source-checked, not clinician-reviewed.
Last updated: 2026-08-19Next planned review: 2027-08-03
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status — Source checked. This page was written with AI assistance and checked line by line against the sources listed on it. That confirms the sources support what the page says. It is not a medical review, and it does not confirm the page is complete or right for your situation.
High-risk topic — talk to your care team. This topic can involve urgent, individual medical decisions. This page is general education only: it cannot tell you whether your situation is an emergency or what you personally should do. Follow your oncology team's instructions and contact them for individual guidance.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status: Source checked — This page was written with AI assistance and checked line by line against the sources listed on it. That confirms the sources support what the page says. It is not a medical review, and it does not confirm the page is complete or right for your situation.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
Read more about our editorial process, our use of AI, and our corrections policy.
Spotted a problem? Report an error — a factual mistake, broken or outdated source, confusing wording, or anything that seems unsafe. Please do not include names, medical record numbers, dates of birth, addresses, or other identifying medical information in your report.
After using this page, do you understand what to do next?
Anonymous — we only record the answer, never who gave it.
Related articles
Still have questions?
Educational answers, plain language
Free to print and share